VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 464 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2014. The put-call ratio across all filers is 1.12 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $131,000 | -15.5% | 9,041 | +42.7% | 0.00% | -20.0% |
Q3 2016 | $155,000 | -46.4% | 6,335 | -55.9% | 0.01% | -50.0% |
Q2 2016 | $289,000 | +60.6% | 14,349 | +109.7% | 0.01% | +25.0% |
Q1 2016 | $180,000 | -29.4% | 6,842 | +172.7% | 0.01% | -33.3% |
Q4 2015 | $255,000 | -81.1% | 2,509 | -66.8% | 0.01% | -88.6% |
Q3 2015 | $1,347,000 | -11.3% | 7,554 | +10.6% | 0.10% | -2.8% |
Q2 2015 | $1,518,000 | +37.7% | 6,831 | +23.1% | 0.11% | +40.3% |
Q1 2015 | $1,102,000 | +125.4% | 5,548 | +62.3% | 0.08% | +45.3% |
Q4 2014 | $489,000 | +12.7% | 3,418 | +3.4% | 0.05% | +1.9% |
Q3 2014 | $434,000 | -47.1% | 3,305 | -49.1% | 0.05% | -52.7% |
Q2 2014 | $820,000 | -53.4% | 6,499 | -51.2% | 0.11% | -14.1% |
Q1 2014 | $1,758,000 | +71.8% | 13,328 | +53.0% | 0.13% | -17.9% |
Q4 2013 | $1,023,000 | +33.0% | 8,713 | +18.2% | 0.16% | +16.4% |
Q3 2013 | $769,000 | +2.9% | 7,372 | -15.0% | 0.13% | -10.7% |
Q2 2013 | $747,000 | – | 8,678 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |